Cargando…

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

BACKGROUND: In the past few years, new drugs made their appearance in the first-line setting of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among them. The present systematic review aims to point out any evidence published to date about first-line treatment with cab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bersanelli, Melissa, Leonardi, Francesco, Buti, Sebastiano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159801/ https://www.ncbi.nlm.nih.gov/pubmed/30288108 http://dx.doi.org/10.2147/CMAR.S160485

Ejemplares similares

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
por: Buti, Sebastiano, et al.
Publicado: (2016)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2017)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2018)

Systemic adjuvant therapies in renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2012)

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2022)

Renal cell carcinoma and viral infections: A dangerous relationship?
por: Bersanelli, Melissa, et al.
Publicado: (2022)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
por: Bersanelli, Melissa, et al.
Publicado: (2014)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
por: Lazzerini, Pietro Enea, et al.
Publicado: (2016)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
por: George, Daniel J., et al.
Publicado: (2019)

From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
por: Kao, Christina C, et al.
Publicado: (2019)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2019)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2020)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab
por: Bersanelli, Melissa, et al.
Publicado: (2019)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
por: Vilela-Martin, José Fernando
Publicado: (2016)

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
por: Cinti, Francesca, et al.
Publicado: (2017)

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
por: Lenert, Aleksander, et al.
Publicado: (2017)

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
por: Levin, Pavel A, et al.
Publicado: (2017)

Review Article “Spotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Date”
por: Hannaford, Andrew, et al.
Publicado: (2021)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_na4mfn2gsf4vi2h87o4gf16jpg